The ATTRibute-CM study's open-label extension showed that acoramidis effectively lowers all-cause mortality in patients with ...
The FDA has granted Fast Track designation to VS-041, an investigational therapy for the treatment of heart failure with preserved ejection fraction.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback